Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to find the best dose of the antibody-drug conjugate LY4101174 to treat advanced bladder and prostate cancers. The people in this study have bladder or prostate cancer that came back or keeps growing after treatment.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Sacituzumab govitecan targets and destroys cells that make a protein called TROP-2. Researchers have found this protein to be expressed on mesothelioma cells. By destroying these cells, sacituzumab govitecan may help slow or stop the growth of your cancer. It is given intravenously (by vein).
Researchers want to find the best dose of TERN-701 to use in people with chronic myeloid leukemia (CML). The people in this study have CML that came back after treatment or could not be treated with standard therapies.
A mutation called G12C in a gene called KRAS may promote cancer growth. LY3537982 is an investigational drug that targets the mutated KRAS G12C protein. This targeting action may stop cancer cells from growing and dividing.
Researchers want to find the best dose of AZD0754 for people with prostate cancer. The patients in this study have prostate cancer that has metastasized (spread).
Researchers want to find the best dose of [AC-225]RTX-2358 to use safely in people with advanced sarcoma. The people in this study have sarcoma that has come back or keeps growing after treatment.
Deficient mismatch repair (dMMR) happens when a cell becomes unable to repair mistakes that happen during the normal process of cell division. Standard treatments for early-stage rectal cancer include chemotherapy, radiation therapy, and surgery. In this study, researchers are assessing the safety and effectiveness of giving the investigational immunotherapy dostarlimab first in people with locally advanced mismatch repair-deficient rectal cancer. Doctors will then evaluate patients' response to treatment before considering standard chemoradiation and/or surgery. Patients whose tumors respond completely to dostarlimab alone can be followed with close surveillance and no surgery.
